Abstract
<title>Abstract</title> Background/Aims : Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) possess anti-inflammatory properties. The purpose of this study was to find out what impact the use of ACEIs and ARBs before ICU admission has on the clinical conditions of patients with sepsis. Methods Patients diagnosed with sepsis were included in this study using data extracted from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. The primary endpoints assessed were the 30- and 90-day mortality rates, along with the length of stay in the intensive care unit (ICU). Statistical analysis was conducted using multivariable Cox regression and linear regression models, while propensity score matching (PSM) was used to ensure the reliability and validity of the results. Results Among the 22,783 patients hospitalized for sepsis. Multivariable Cox regression analysis revealed that the utilization of ACEIs/ARBs was significantly associated with a notable reduction in 90 - day mortality (hazard ratio (HR) = 0.36, 95% confidence interval: 0.33–0.4, p < 0.001). Regarding safety considerations, the use of ACEIs/ARBs was associated with an increased risk of acute kidney injury (AKI) (Odds Ratio (OR) = 1.09, 95% CI: 1.01–1.17, p = 0.026) and a higher incidence of vasopressor drug use (OR = 1.11, 95% CI: 1.04–1.19, p = 0.002). However, ACEIs/ARBs were linked with a reduced need for continuous renal replacement therapy (OR = 0.77, 95% CI: 0.66–0.9, p = 0.001). Conclusions The pre - ICU administration of ACEIs/ARBs to patients with sepsis may be associated with lower mortality rates.
Affiliated Institutions
Related Publications
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19
Rationale: Use of ACEIs (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) is a major concern for clinicians treating coronavirus disease 201...
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction
Background— Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF det...
Association Between Adoption of Evidence-Based Treatment and Survival for Patients With ST-Elevation Myocardial Infarction
Only limited information is available on the speed of implementation of new evidence-based and guideline-recommended treatments and its association with survival in real life he...
Effect of drug therapy on survival in chronic congestive heart failure
A review of the current evidence on the effects of various agents on survival among patients with congestive heart failure (CHF) suggests that angiotensin-converting enzyme inhi...
Declining Mortality in Patients with Acute Renal Failure, 1988 to 2002
Despite improvements in intensive care and dialysis, some experts have concluded that outcomes associated with acute renal failure (ARF) have not improved significantly over tim...
Publication Info
- Year
- 2025
- Type
- article
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.21203/rs.3.rs-8137597/v1